Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 50,477 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CONTROL Clear all
Not listed Phase 3 Interventional

Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer

NCT00022373
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
iseganan HCl oral solution, management of therapy complications
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris

NCT04724473
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Cream 0.025%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,030 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Not applicable Interventional

Comparing the Effectiveness of Lung Expansion Therapy in Adult Human Subjects

NCT02892773
View directory record Official record
Conditions
Atelectasis
Interventions
Incentive Spirometry, EzPAP® Positive Airway Pressure
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 79 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Early Phase 1 Interventional

Medrol Dose Packs for Post-Operative Pain Control

NCT06453083
View directory record Official record
Conditions
Pain
Interventions
Placebo, Medrol
Drug
Lead sponsor
University of Utah
Other
Eligibility
10 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 20, 2026, 4:07 PM EDT
Enrolling by invitation Not applicable Interventional

Dry Needling and Exercise for Mid-portion Achilles Tendinopathy

NCT07642583
View directory record Official record
Conditions
Non-Insertional Achilles Tendinopathy
Interventions
Dry needling, Sham dry needling
Other
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy

NCT00988741
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
ARQ 197, Placebo
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Not applicable Interventional

Epigenetic Impact of a Psychotherapeutic Program in Adolescents With Severe Adverse Experiences

NCT04103541
View directory record Official record
Conditions
Children Exposed to Adverse Experiences
Interventions
IP-Colombia
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
13 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 4:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Research Study Exploring How Musculoskeletal Function and the Autonomic Nervous System Relate to Visceral Pain in Women With and Without Dysmenorrhea (Painful Periods).

NCT07209566
View directory record Official record
Conditions
Dysmenorrhea, Dysmenorrhea Primary, Visceral Pain, Menstrual Pain
Interventions
Visceral Pain Stimulus
Diagnostic Test
Lead sponsor
Azusa Pacific University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Art Therapy in Obstetric Patients

NCT05503056
View directory record Official record
Conditions
Pregnancy Related, Depression
Interventions
art therapy, nothing
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 20, 2026, 4:07 PM EDT
Active, not recruiting Phase 3 Interventional

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756
View directory record Official record
Conditions
Arteriosclerosis, Hypercholesterolaemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
14,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
132
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Recruiting Phase 2 Interventional

Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial

NCT07650656
View directory record Official record
Conditions
High Grade Sarcoma, Sarcoma
Interventions
Electronic Health Record Review, Fluorescence Imaging, Fluorescence-Guided Surgery, Indocyanine Green, Questionnaire Administration, Resection
Other · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

NCT03451422
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Efavaleukin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Anniston, Alabama • Beverly Hills, California • Aventura, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 20, 2026, 4:07 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Connected Through Coaching for Flourishing Families

NCT06145451
View directory record Official record
Conditions
Maltreatment by Parent
Interventions
Family Success Network
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 1 Interventional

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

NCT00117429
View directory record Official record
Conditions
HIV Infections
Interventions
HIV gp120/NefTat/AS02A Vaccine
Biological
Lead sponsor
Marcus Altfeld, M.D., Ph.D.
Individual
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 20, 2026, 4:07 PM EDT
Withdrawn Not applicable Interventional

The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma

NCT02524431
View directory record Official record
Conditions
Glaucoma
Interventions
Collection of trabecular meshwork tissue during surgery
Other
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

NCT04072302
View directory record Official record
Conditions
Malaria
Interventions
KAF156, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 40 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

NCT01209702
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
tocilizumab, Placebo
Biological · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Huntington Beach, California • Aventura, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 20, 2026, 4:07 PM EDT
Recruiting Not applicable Interventional

Perelel Prenatal Supplements vs. Generic Prenatal Supplements and Health of Mother and Baby (SUPPORT)

NCT07046845
View directory record Official record
Conditions
Pregnancy
Interventions
Perelel Prenatal Vitamin, Generic Prenatal Vitamin
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Not applicable Interventional

Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats

NCT01683045
View directory record Official record
Conditions
Persistent Atrial Fibrillation
Interventions
The Estech COBRA® Surgical System
Device
Lead sponsor
Endoscopic Technologies, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Mesa, Arizona • Hartford, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Phase 3 Interventional Results available

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

NCT01316939
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786A, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 20, 2026, 4:07 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

NCT07355075
View directory record Official record
Conditions
Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
Interventions
GX-03, Vehicle
Combination Product · Other
Lead sponsor
Turn Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Irving, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 20, 2026, 4:07 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

NCT04875975
View directory record Official record
Conditions
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Interventions
Rozanolixizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 20, 2026, 4:07 PM EDT
Completed Phase 2 Interventional

Acute Effects of Exercise in Smokers With Schizophrenia

NCT01635075
View directory record Official record
Conditions
Tobacco Dependence, Cigarette Craving, Smoking Behavior
Interventions
Exercise, passive control
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 20, 2026, 4:07 PM EDT